Compare Ascendis Pharma A/S (ASND) vs Harmony Gold Mining Co. (HMY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Harmony Gold Mining Co. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Harmony Gold Mining Co. trades at $15.09 (market cap $9.43B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 2.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | HMY | |
|---|---|---|
Market Cap | $17.74B | $9.43B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $26.04 |
52-Week Low | $163.32 | $12.61 |
Enterprise Value | $18.11B | $9.77B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Harmony Gold Mining (HMY) trades at $15.11, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong 2024 results with $61.38B revenue and $8.59B net income, showing improved margins. Recent earnings have been mixed, beating in Q2 2025 but missing in Q4 2025. A dividend of $0.31 is scheduled for May 2026. Analyst consensus is predominantly Hold (70%), with 10% Buy and 20% Sell ratings.
HMY presents a valuation opportunity with a low P/E of 9.67 and EV/EBITDA of 5.06, supported by robust profitability metrics like 20.06% net margin and 32.32% ROE. However, risks include gold price sensitivity to Fed rate hikes, operational execution in transitioning to gold-copper hybrid model, and bearish technical trends. The stock's outlook balances fundamental strength against macroeconomic and sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →
